Preclinical Oncology Models for Testing Immunotherapies

4T1 is a triple-negative mouse breast cancer cell line. Pharmatest utilises a 4T1 cell line with stable expression of green fluorescent protein (GFP) enabling easy and efficient detection of whole-body tumour burden.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news

Related Links:

Authors: Altinoz MA, Ozpinar A, Alturfan EE, Elmaci I Abstract Vinorelbine is a very potent chemotherapeutic agent which is used to treat a number of cancers including breast and non-small cell lung tumors. Vinorelbine mainly acts via blocking microtubules and induces a specific type of cell death called 'mitotic catastrophe/apoptosis' subsequent to mitotic slippage, which is the failure of cells to stay in a mitotic arrested state and replicating their DNA without cytokinesis. Glial tumor cells are especially sensitive to mitotic slippage. In recent years, vinorelbine demonstrated potency in pediatric optic and po...
Source: Journal of Chemotherapy - Category: Cancer & Oncology Tags: J Chemother Source Type: research
We examined control patients from two randomized phase II trials that tested HER2-peptide vaccines to determine the effect of HLA-A2 status and HER2 expression on disease-free survival. The analysis showed that HLA-A2-status does not affect disease-free survival, regardless of HER2 expression suggesting that HLA-A2 negative patients can be used as control patients. Additionally, HER2 over-expression was associated with a better disease-free survival in this population, underscoring the need for additional therapies in HER2 low-expressing breast cancer. ClinicalTrials.gov Identifier: NCT00524277. PMID: 30025819 [PubMed...
Source: Clinical Immunology - Category: Allergy & Immunology Authors: Tags: Clin Immunol Source Type: research
Conclusions: WBRT remains the cornerstone of the management of brain metastases. The present study concludes that the survival of patients with brain metastases is significantly improved with female gender, good PS, primary breast cancer, time lag of>6 months between diagnosis of the primary tumor and development of brain metastases, solitary lesion, and controlled primary tumor.
Source: Indian Journal of Palliative Care - Category: Palliative Care Authors: Source Type: research
We presently forget 98% of everything we experience. That will go away in favor of perfect, controllable, configurable memory. Skills and knowledge will become commodities that can be purchased and installed. We will be able to feel exactly as we wish to feel at any given time. How we perceive the world will be mutable and subject to choice. How we think, the very fundamental basis of the mind, will also be mutable and subject to choice. We will merge with our machines, as Kurzweil puts it. The boundary between mind and computing device, between the individual and his or her tools, will blur. Over the course of the ...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Publication date: Available online 19 June 2018Source: Pharmacology &TherapeuticsAuthor(s): Filipa Lynce, Ayesha N. Shajahan-Haq, Sandra M. SwainAbstractDysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a new therapeutic opportunity for estrogen receptor positive breast cancer. Initial pan-CDK inhibitors were associated with extensive toxicities but in recent years, the development of potent specific CDK inhibitors with favorable tolerability has driven renewed interests in this class of targeted therapies. Palbociclib, ribociclib and abemaciclib are specific CDK4/6 inhibitors that h...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 25 May 2018Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Yaqin Shi, Fang Yang, Doudou Huang, Xiaoxiang GuanAbstractAndrogen receptor (AR) targeted treatment has shown promising preliminary results in triple negative breast cancer (TNBC). Identification of AR-associated signaling pathways is of great significance for in-depth understanding of their roles in pathogenesis of TNBC. To meet this objective, preclinical and clinical studies were conducted to clarify the biological interactions of AR signaling and combination strategies based on AR-targeted therapy. Bi...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 5 April 2018Source: Acta Pharmaceutica Sinica BAuthor(s): Zijun Zhao, Yu Chen, Ngiambudulu M. Francisco, Yuanqing Zhang, Minhao WuAbstractChimeric antigen receptor T cell (CAR-T cell) therapy is a novel adoptive immunotherapy where T lymphocytes are engineered with synthetic receptors known as chimeric antigen receptors (CAR). The CAR-T cell is an effector T cell that recognizes and eliminates specific cancer cells, independent of major histocompatibility complex molecules. The whole procedure of CAR-T cell production is not well understood. The CAR-T cell has been used predominantly in t...
Source: Acta Pharmaceutica Sinica B - Category: Cancer & Oncology Source Type: research
National Cancer Institute (NCI) researchers recently reported complete and durable regression of chemorefractory metastaticERBB2-negative and ER-positive breast cancer in a woman who received an experimental immunotherapy. Thecase report, published recently inNature Medicine, involved a 49-year-old patient whose late-stage cancer was progressing despite multiple lines of chemotherapy and hormone treatments.
Source: JAMA - Category: General Medicine Source Type: research
Publication date: Available online 19 June 2018Source: Pharmacology &TherapeuticsAuthor(s): Filipa Lynce, Ayesha N. Shajahan-Haq, Sandra M. SwainAbstractDysregulation of the cyclin dependent kinase pathway in luminal breast cancer creates a new therapeutic opportunity for estrogen receptor positive breast cancer. Initial pan-CDK inhibitors were associated with extensive toxicities but in recent years, the development of potent specific CDK inhibitors with favorable tolerability has driven renewed interests in this class of targeted therapies. Palbociclib, ribociclib and abemaciclib are specific CDK4/6 inhibitors that h...
Source: Pharmacology and Therapeutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 2 November 2017Source: Seminars in Cancer BiologyAuthor(s): D. Hammerl, M. Smid, A.M. Timmermans, S. Sleijfer, J.W.M. Martens, R. DebetsAbstractThere is an increasing awareness of the importance of tumor – immune cell interactions to the evolution and therapy responses of breast cancer (BC). Not surprisingly, numerous studies are currently assessing the clinical value of immune modulation for BC patients. However, till now durable clinical responses are only rarely observed. It is important to realize that BC is a heterogeneous disease comprising several histological and molecular s...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Immunotherapy | Pharmaceuticals